Retrieved from Gentile, V., Vicini, P., Prigiotti, G., Koverech, A., & Di Silverio, F
However, newer medications target multiple metabolic hormones: GLP-1 drugs (single-hormone): semaglutide medications like Wegovy and Ozempic Dual-agonist drugs: tirzepatide medications like Mounjaro and Zepbound (target GLP-1 and GIP receptors) Triple-agonist drugs: retatrutide (targets GLP-1, GIP and glucagon receptors) Researchers believe stimulating multiple hormone pathways may produce stronger effects on appetite, metabolism and energy expenditure
Retatrutide is a triple agonist, meaning it activates GIP, GLP-1, and glucagon receptors at the same time
Risk of myocardial infarction in patients with psoriasis